Reported 2 days ago
Hims & Hers (HIMS) saw its stock rise by 6.76% on Friday, closing at $49.41, following the CEO's assurance of continuing to produce affordable compounded versions of GLP-1 weight-loss drugs after terminating its partnership with Novo Nordisk. CEO Andrew Dudum expressed his commitment to advocate for customers despite Novo Nordisk's claims of legal violations and deceptive marketing practices by Hims & Hers.
Source: YAHOO